A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Immunome Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 38,100 shares of IMNM stock, worth $401,573. This represents 0.0% of its overall portfolio holdings.

Number of Shares
38,100
Previous 28,100 35.59%
Holding current value
$401,573
Previous $340,000 63.82%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$11.54 - $22.11 $48,087 - $92,132
4,167 New
4,167 $50,000
Q4 2023

Feb 14, 2024

SELL
$7.3 - $10.73 $35,499 - $52,179
-4,863 Reduced 64.9%
2,630 $28,000
Q3 2023

Nov 14, 2023

BUY
$6.17 - $9.16 $39,450 - $58,569
6,394 Added 581.8%
7,493 $62,000
Q2 2023

Aug 14, 2023

SELL
$4.7 - $7.91 $8,652 - $14,562
-1,841 Reduced 62.62%
1,099 $8,000
Q1 2023

May 15, 2023

BUY
$3.26 - $5.69 $9,584 - $16,728
2,940 New
2,940 $14,000

Others Institutions Holding IMNM

About Immunome Inc.


  • Ticker IMNM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,127,400
  • Market Cap $128M
  • Description
  • Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product ca...
More about IMNM
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.